

**TIRBANIBULIN ointment (Klisyri<sup>®</sup> ▼) for the treatment of actinic keratosis**

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of TIRBANIBULIN ointment (Klisyri<sup>®</sup> ▼) for the treatment of actinic keratosis.**

**GREY**

Tirbanibulin is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. <sup>[1]</sup>

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, treatment of actinic keratosis should continue to follow national guidance, local pathways and local formulary choices:

- > British Association of Dermatologists: [British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017](#) (published 18 July 2017)
- > Pan Mersey APC Formulary: [Photodamage](#)

**References**

1. Almirall Limited. Summary of Product Characteristics; [Klisyri 10 mg/g ointment](#), 02 August 2021. Accessed online 14 October 2021.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.